Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Obes (Lond). 2013 May;37(5):699-703. doi: 10.1038/ijo.2012.116. Epub 2012 Jul 17.

CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans.

Author information

  • 1Minerva Foundation Institute for Medical Research, Helsinki, Finland.

Abstract

OBJECTIVE:

Studies in mice have suggested that endocannabinoid blockade using the cannabinoid receptor type 1 (CB1) blocker rimonabant prevents obesity-induced hepatic steatosis.

DESIGN AND SUBJECTS:

To determine effects of rimonabant on liver fat in humans, we measured liver fat content by proton magnetic resonance spectroscopy in 37 subjects who used either a CB1 blocker rimonabant or placebo in a double-blind, randomized manner. This was retrospectively compared with a historical hypocaloric diet weight loss group (n=23).

RESULTS:

Weight loss averaged 8.5±1.4 kg in the rimonabant, 1.7±1.0 kg in the placebo and 7.5±0.2 kg in the hypocaloric diet group (P<0.001, rimonabant vs placebo; NS, rimonabant vs hypocaloric diet). Liver fat decreased more in the rimonabant (5.9% (2.5-14.6%) vs 1.8% (0.9-3.5%), before vs after) than in the placebo group (6.8% (2.2-15.7%) vs 4.9% (1.6-7.8%), before vs after, P<0.05). The percentage change in body weight correlated closely with the percentage loss of liver fat (r=0.70, P>0.0001). The decreases in liver fat were comparable between the rimonabant and the young historical hypocaloric diet groups.

CONCLUSIONS:

We conclude that, unlike in mice, in humans rimonabant decreases liver fat in proportion to weight loss.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk